Business Wire
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
➖
AI Sentiment
Neutral
5/10
- Home
- TVTX
as of 02-11-2026 4:00pm EST
$30.22
$0.10
-0.33%
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.3B | IPO Year: | N/A |
| Target Price: | $37.43 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $42.13 | Next Earning Date: | 02-19-2026 |
| Revenue: | $435,826,000 | Revenue Growth: | 114.22% |
| Revenue Growth (this year): | 121.25% | Revenue Growth (next year): | 36.79% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -58907000.0 | FCF Growth: | N/A |
AI-Powered TVTX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.70%
70.70%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
REED ELIZABETH E
Sell
Chief Legal Officer and GC
TVTX Feb 4, 2026
Avg Cost/Share
$32.41
Shares
2,994
Total Value
$96,358.61
Owned After
105,211
Cline Christopher R.
Sell
CHIEF FINANCIAL OFFICER
TVTX Feb 4, 2026
Avg Cost/Share
$32.52
Shares
1,745
Total Value
$56,167.90
Owned After
111,336
Inrig Jula
Sell
CHIEF MEDICAL OFFICER
TVTX Feb 4, 2026
Avg Cost/Share
$32.48
Shares
1,779
Total Value
$57,295.37
Owned After
105,706
Dube Eric M
Sell
CHIEF EXECUTIVE OFFICER
TVTX Feb 3, 2026
Avg Cost/Share
$32.38
Shares
100,087
Total Value
$3,230,315.62
Owned After
432,886
ROTE WILLIAM E.
Sell
Chief Research Officer
TVTX Feb 3, 2026
Avg Cost/Share
$32.87
Shares
12,446
Total Value
$409,100.02
Owned After
109,087
SEC Form 4
Calvin Sandra
Sell
SVP, CHIEF ACCOUNTING OFFICER
TVTX Feb 3, 2026
Avg Cost/Share
$32.12
Shares
4,333
Total Value
$139,175.96
Owned After
49,080
SEC Form 4
REED ELIZABETH E
Sell
Chief Legal Officer and GC
TVTX Feb 3, 2026
Avg Cost/Share
$32.12
Shares
7,175
Total Value
$230,461.00
Owned After
105,211
SEC Form 4
Heerma Peter
Sell
CHIEF COMMERCIAL OFFICER
TVTX Feb 3, 2026
Avg Cost/Share
$32.12
Shares
7,310
Total Value
$234,797.20
Owned After
131,823
SEC Form 4
Cline Christopher R.
Sell
CHIEF FINANCIAL OFFICER
TVTX Feb 3, 2026
Avg Cost/Share
$32.12
Shares
7,242
Total Value
$232,613.04
Owned After
111,336
SEC Form 4
Inrig Jula
Sell
CHIEF MEDICAL OFFICER
TVTX Feb 3, 2026
Avg Cost/Share
$32.12
Shares
6,956
Total Value
$223,426.72
Owned After
105,706
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Feb 4, 2026 | Sell | $32.41 | 2,994 | $96,358.61 | 105,211 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Feb 4, 2026 | Sell | $32.52 | 1,745 | $56,167.90 | 111,336 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 4, 2026 | Sell | $32.48 | 1,779 | $57,295.37 | 105,706 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Feb 3, 2026 | Sell | $32.38 | 100,087 | $3,230,315.62 | 432,886 | |
| ROTE WILLIAM E. | TVTX | Chief Research Officer | Feb 3, 2026 | Sell | $32.87 | 12,446 | $409,100.02 | 109,087 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Feb 3, 2026 | Sell | $32.12 | 4,333 | $139,175.96 | 49,080 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Feb 3, 2026 | Sell | $32.12 | 7,175 | $230,461.00 | 105,211 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Feb 3, 2026 | Sell | $32.12 | 7,310 | $234,797.20 | 131,823 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Feb 3, 2026 | Sell | $32.12 | 7,242 | $232,613.04 | 111,336 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Feb 3, 2026 | Sell | $32.12 | 6,956 | $223,426.72 | 105,706 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Compare TVTX vs Leading Stocks
See how TVTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.